Takahashi, Fuyuko
Hashimoto, Yoshitaka http://orcid.org/0000-0002-8794-0550
Okada, Hiroshi
Kondo, Yuriko
Kaji, Ayumi
Sakai, Ryosuke
Kawate, Yuka
Okamura, Takuro
Nakanishi, Naoko
Majima, Saori
Senmaru, Takafumi
Ushigome, Emi
Hamaguchi, Masahide
Asano, Mai
Yamazaki, Masahiro
Fukui, Michiaki
Article History
Received: 19 April 2022
Accepted: 28 March 2023
First Online: 7 April 2023
Declarations
:
: The present study was approved by the Research Ethics Committee of Kyoto Prefectural University of Medicine (No. RBMR-E-466-6) and was conducted in accordance with the principles of the Declaration of Helsinki. All participants submitted written informed consent.
: Not applicable.
: Hashimoto Y received personal fees from Novo Nordisk Pharma Ltd., Mitsubishi Tanabe Pharma Corp., Kowa Company Ltd., Sanofi K.K., Takeda Pharmaceutical Co., Ltd., Ono Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., and Sumitomo Dainippon Pharma Co., Ltd., outside of the submitted work. Okada H received grant support from the Japan Society for the Promotion of Science, and personal fees from Daiichi Sankyo Co., Ltd., Takeda Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Novo Nordisk Pharma Ltd., MSD K.K., Kyowa Hakko Kirin Company Ltd., Kowa Pharmaceutical Co., Ltd., Eli Lilly Japan K.K., Ono Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., Sanofi K.K., and Mitsubishi Tanabe Pharma Corporation. Nakanishi N received grant support from Japan Society for the Promotion of Science (JSPS KAKENHI grant numbers: 19K23999 and 20K16158) and The Japan Food Chemical Research Foundation, and personal fees from Novo Nordisk Pharma Ltd., and Kowa Pharmaceutical Co., Ltd. Osaka T received grants from Combi Corporation, and personal fees from Toa Eiyo Corp., Mitsubishi Tanabe Pharma Corp., Daiichi Sankyo Co., Ltd., Novo Nordisk Pharma Ltd., Nippon Boehringer Ingelheim Co., Ltd., Ono Pharmaceutical Co., Ltd., Kyowa Kirin Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., MSD K.K., Takeda Pharmaceutical Co., Ltd., Kowa Pharma Co., LTD., Eli Lilly Japan K.K., and AstraZeneca K.K., outside of the submitted work. Senmaru T received personal fees from Kyowa Hakko Kirin Co., Ltd., Astellas Pharma Inc., Mitsubishi Tanabe Pharma Co., Kowa Pharma Co., Ltd., Sanofi K.K., Taisho Toyama Pharma Co., Ltd., Kissei Pharma Co., Ltd., MSD K.K., Novo Nordisk Pharma Ltd., Ono Pharma Co., Ltd., Eli Lilly Japan K.K., and Takeda Pharma Co., Ltd., outside of the submitted work. Ushigome E received grant support from the Japanese Study Group for Physiology and Management of Blood Pressure, Astellas Foundation for Research on Metabolic Disorders (grant number: 4024), Japan Society for the Promotion of Science, Mishima Kaiun Memorial Foundation, and personal fees from Sumitomo Dainippon Pharma Co., Ltd., Mitsubishi Tanabe Pharma Corporation, Nippon Boehringer Ingelheim Co., Ltd., Sanofi K.K., Kowa Pharmaceutical Co., Ltd., Daiichi Sankyo Co., Ltd., Kyowa Hakko Kirin Co., Ltd., AstraZeneca K.K., Novo Nordisk Pharma Ltd., Ono Pharmaceutical Co., Ltd., Taisho Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Ltd., and MSD K.K., outside of the submitted work. Donated Fund Laboratory of Diabetes therapeutics is an endowment department, supported with an unrestricted grant from Taiyo Kagaku Co., Ltd., Taisho Pharmaceutical Co., Ltd., and Ono Pharmaceutical Co., Ltd. Hamaguchi M received grants from Yamada Bee Farm, Oishi Kenko Inc., Nippon Boehringer Ingelheim Co., Ltd., AstraZeneca K.K., and Ono Pharma Co., Ltd., and personal fees from Eli Lilly, Japan, Sanofi K.K., Sumitomo Dainippon Pharma Co., Ltd., Daiichi Sankyo Co., Ltd., Mitsubishi Tanabe Pharma Corp., AstraZeneca K.K., Ono Pharma Co., Ltd., and Kowa Pharma Co., Ltd., outside of the submitted work. Asano M received personal fees from Takeda Pharmaceutical Co., Ltd., Kowa Pharmaceutical Co., Ltd., AstraZeneca K.K., Ono Pharmaceutical Co., Ltd., Abbott Japan Co., Ltd., Novo Nordisk Pharma Ltd., Chugai Pharmaceutical Co., Ltd., and Sumitomo Dainippon Pharma Co., Ltd., outside of the submitted work. Yamazaki M received personal fees from Sumitomo Dainippon Pharma Co., Ltd., Kowa Pharmaceutical Co., Ltd., Takeda Pharmaceutical Company Limited, Kyowa Hakko Kirin Co., Ltd., Kowa Company, Limited, Daiichi Sankyo Co., Ltd., Ono Pharmaceutical Co., Ltd., AstraZeneca PLC, and MSD K.K., outside of the submitted work. Fukui M received grants from Eli Lilly, Japan, K.K., Nippon Boehringer Ingelheim Co., Ltd., Sanwa Kagagu Kenkyusho Co., Ltd., Oishi Kenko Inc., MSD K.K., Kowa Pharma Co., Ltd., Kissei Pharma Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Ono Pharma Co. Ltd., Mitsubishi Tanabe Pharma Corp., Abbott Japan Co., Ltd., Daiichi Sankyo Co., Ltd., Johnson & Johnson K.K. Medical Co., Astellas Pharma Inc., Kyowa Kirin Co., Ltd., Novo Nordisk Pharma Ltd., Yamada Bee Farm, Taisho Pharma Co., Ltd., Terumo Corp., Takeda Pharma Co., Ltd., Tejin Pharma Ltd., Sanofi K.K., Nippon Chemiphar Co., Ltd., and TERUMO CORPORATION, and personal fees from Astellas Pharma Inc., Nippon Boehringer Ingelheim Co., Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., MSD K.K., Mochida Pharma Co., Ltd., Eli Lilly Japan K.K., Kissei Pharma Co., Ltd., AstraZeneca K.K., Mitsubishi Tanabe Pharma Corp., TERUMO CORPORATION, Daiichi Sankyo Co., Ltd., Bayer Yakuhin, Ltd., Takeda Pharma Co., Ltd., Teijin Pharma Ltd., Ono Pharma Co., Ltd., Taisho Pharma Co., Ltd., Kyowa Kirin Co., Ltd., Abbott Japan Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Arkray Inc., Medtronic Japan Co., Ltd., Novo Nordisk Pharma Ltd., Kowa Pharma Co., Ltd., Nipro Corp., and Sanofi K.K., outside of the submitted work. The other authors have nothing to disclose.